StudyType	PubMedID	Author	Title	Journal	PublishDate	Chromosome	Disease	Technology	Species	CaseID	Platform	CNA	Connection	Gene	Affiliation	Abstract	GenomeAssembly	GEO	dbGaP	ENA	IsCancer	FusionGene
Research	24613276	Laurie CC, Laurie CA, Smoley SA, Carlson EE, Flinn I, Fridley BL, Greisman HA, Gribben JG, Jelinek DF, Nelson SC, Paietta E, Schaid D, Sun Z, Tallman MS, Weinshilboum R, Kay NE, Shanafelt TD	Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants	Cancer Genetics	2014 Jan	11	Chronic lymphocytic leukemia	SNP Array	Homo sapiens	10	Illumina HumanOmni-Quad v1.0_B SNP microarray	chr10:0-88086:0;chr10:1333199-135374737:0;chr10:88087-1333198:-1;chr11:0-15590802:0;chr11:115677786-118336936:0;chr11:118336937-126720615:-1;chr11:126720616-128026677:0;chr11:128026678-134367886:-1;chr11:134367887-134452384:0;chr11:15590803-16626283:-1;chr11:16626284-34146998:0;chr11:34146999-34894477:-1;chr11:34894478-35227176:0;chr11:35227177-43341509:-1;chr11:43341510-48614745:0;chr11:48614746-51417246:-1;chr11:51417247-54508765:0;chr11:54508766-59693555:-1;chr11:59693556-77902555:0;chr11:77902556-83268891:-1;chr11:83268892-83735129:0;chr11:83735130-84917636:-1;chr11:84917637-86301560:0;chr11:86301561-88846159:-1;chr11:88846160-88994233:0;chr11:88994234-91701474:-1;chr11:91701475-95876561:0;chr11:95876562-115677785:-1;chr12:0-132349534:0;chr13:0-114142980:0;chr14:0-106368585:0;chr15:0-100338915:0;chr16:0-88827254:0;chr17:0-78774742:0;chr18:0-76117153:0;chr19:0-63811651:0;chr1:0-247249719:0;chr20:0-62435964:0;chr21:0-46944323:0;chr22:0-49691432:0;chr2:0-35281164:0;chr2:35281165-39625508:-1;chr2:39625509-53383060:0;chr2:53383061-54247074:-1;chr2:54247075-55473113:0;chr2:55473114-55837433:-1;chr2:55837434-56709282:0;chr2:56709283-59433830:-1;chr2:59433831-242951149:0;chr3:0-199501827:0;chr4:0-70092923:0;chr4:121277543-123877604:-1;chr4:123877605-191273063:0;chr4:70092924-73761895:-1;chr4:73761896-77315141:0;chr4:77315142-90447261:-1;chr4:90447262-121277542:0;chr5:0-180857866:0;chr6:0-170899992:0;chr7:0-158821424:0;chr8:0-146274826:0;chr9:0-140273252:0;chrX:0-154913754:0;chrY:0-57772954:0			Biostatistics Department, University of Washington, Seattle, WA, USA	Pretherapy patients with chronic lymphocytic leukemia (CLL) from US Intergroup trial E2997 were analyzed with single nucleotide polymorphism microarrays to detect acquired chromosomal anomalies. The four CLL-typical anomalies (11q-, +12, 13q-, and 17p-) were found at expected frequencies. Acquired anomalies in other regions account for 70% of the total detected anomalies, and their number per participant has a significant effect on progression-free survival after adjusting for the effects of 17p- (and other covariates). These results were compared with those from a previous study of more than 50,000 participants from the GENEVA consortium of genome-wide association studies, which analyzed individuals with a variety of medical conditions and healthy controls. The percentage of individuals with acquired anomalies is vastly different between the two studies (GENEVA 0.8%; E2997 80%). The composition of the anomalies also differs, with GENEVA having a higher percentage of acquired uniparental disomies and a lower percentage of deletions. The four common CLL anomalies are among the most frequent in GENEVA participants, some of whom may have CLL-precursor conditions or early stages of CLL. However, the patients from E2997 (and other studies of symptomatic CLL) have recurrent acquired anomalies that were not found in GENEVA participants, thus identifying genomic changes that may be unique to symptomatic stages of CLL. 	NCBI 36/hg18		phs000621		Yes	NA
Research	24613276	Laurie CC, Laurie CA, Smoley SA, Carlson EE, Flinn I, Fridley BL, Greisman HA, Gribben JG, Jelinek DF, Nelson SC, Paietta E, Schaid D, Sun Z, Tallman MS, Weinshilboum R, Kay NE, Shanafelt TD	Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants	Cancer Genetics	2014 Jan	9	Chronic lymphocytic leukemia	SNP Array	Homo sapiens	86	Illumina HumanOmni-Quad v1.0_B SNP microarray	chr10:0-135374737:0;chr11:0-129814088:0;chr11:129814089-134443680:-1;chr11:134443681-134452384:0;chr12:0-132349534:0;chr13:0-18086615:0;chr13:18086616-26402964:-1;chr13:26402965-114142980:0;chr14:0-67341733:0;chr14:67341734-92271752:-1;chr14:92271753-106368585:0;chr15:0-18421385:0;chr15:18421386-39191343:-1;chr15:39191344-39197996:0;chr15:39197997-41345866:-1;chr15:41345867-100338915:0;chr16:0-88827254:0;chr17:0-7213:0;chr17:19280415-78774742:0;chr17:7214-19280414:-1;chr18:0-76117153:0;chr19:0-63811651:0;chr1:0-247249719:0;chr20:0-62435964:0;chr21:0-13591801:0;chr21:13591802-23456930:-1;chr21:23456931-46944323:0;chr22:0-49691432:0;chr2:0-40813:0;chr2:208997028-231626311:-1;chr2:231626312-242951149:0;chr2:40814-88909336:1;chr2:88909337-208997027:0;chr3:0-199501827:0;chr4:0-191273063:0;chr5:0-180857866:0;chr6:0-9769250:0;chr6:45857783-57482074:-1;chr6:57482075-61949076:0;chr6:61949077-66859614:-1;chr6:66859615-66865882:0;chr6:66865883-67814410:-1;chr6:67814411-67827225:0;chr6:67827226-74890125:-1;chr6:74890126-74907772:0;chr6:74907773-75471929:-1;chr6:75471930-170899992:0;chr6:9769251-45857783:-1;chr7:0-158821424:0;chr8:0-185253:0;chr8:185254-38182392:-1;chr8:38182393-146274826:0;chr9:0-36586:0;chr9:105644055-109189988:0;chr9:109189989-110587420:-1;chr9:110587421-117495647:0;chr9:117495648-140186312:-1;chr9:140186313-140273252:0;chr9:14484389-16800346:0;chr9:16800347-22040873:-1;chr9:22040874-25320809:0;chr9:25320810-33808257:-1;chr9:33808258-67656949:0;chr9:36587-6530540:1;chr9:6530541-9876402:0;chr9:67656950-84950566:-1;chr9:84950567-91964998:0;chr9:91964999-92295939:-1;chr9:92295940-92675795:0;chr9:92675796-94618312:-1;chr9:94618313-96040218:0;chr9:96040219-96470652:-1;chr9:96470653-99476878:0;chr9:9876403-14484388:-1;chr9:99476879-105644054:-1;chrX:0-154913754:0;chrY:0-57772954:0			Biostatistics Department, University of Washington, Seattle, WA, USA	Pretherapy patients with chronic lymphocytic leukemia (CLL) from US Intergroup trial E2997 were analyzed with single nucleotide polymorphism microarrays to detect acquired chromosomal anomalies. The four CLL-typical anomalies (11q-, +12, 13q-, and 17p-) were found at expected frequencies. Acquired anomalies in other regions account for 70% of the total detected anomalies, and their number per participant has a significant effect on progression-free survival after adjusting for the effects of 17p- (and other covariates). These results were compared with those from a previous study of more than 50,000 participants from the GENEVA consortium of genome-wide association studies, which analyzed individuals with a variety of medical conditions and healthy controls. The percentage of individuals with acquired anomalies is vastly different between the two studies (GENEVA 0.8%; E2997 80%). The composition of the anomalies also differs, with GENEVA having a higher percentage of acquired uniparental disomies and a lower percentage of deletions. The four common CLL anomalies are among the most frequent in GENEVA participants, some of whom may have CLL-precursor conditions or early stages of CLL. However, the patients from E2997 (and other studies of symptomatic CLL) have recurrent acquired anomalies that were not found in GENEVA participants, thus identifying genomic changes that may be unique to symptomatic stages of CLL. 	NCBI 36/hg18		phs000621		Yes	NA
Research	24613276	Laurie CC, Laurie CA, Smoley SA, Carlson EE, Flinn I, Fridley BL, Greisman HA, Gribben JG, Jelinek DF, Nelson SC, Paietta E, Schaid D, Sun Z, Tallman MS, Weinshilboum R, Kay NE, Shanafelt TD	Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants	Cancer Genetics	2014 Jan	9	Chronic lymphocytic leukemia	SNP Array	Homo sapiens	203	Illumina HumanOmni-Quad v1.0_B SNP microarray	chr10:0-135374737:0;chr11:0-134452384:0;chr12:0-132349534:0;chr13:0-114142980:0;chr14:0-106368585:0;chr15:0-100338915:0;chr16:0-88827254:0;chr17:0-78774742:0;chr18:0-76117153:0;chr19:0-63811651:0;chr1:0-247249719:0;chr20:0-62435964:0;chr21:0-46944323:0;chr22:0-49691432:0;chr2:0-242951149:0;chr3:0-38410:0;chr3:17985707-38126735:-1;chr3:38126736-52498444:0;chr3:38411-9799651:-1;chr3:52498445-57909692:-1;chr3:57909693-71780450:0;chr3:71780451-90525615:-1;chr3:90525616-199501827:0;chr3:9799652-17985706:0;chr4:0-175186278:0;chr4:175186279-183245566:-1;chr4:183245567-184392508:0;chr4:184392509-191176659:-1;chr4:191176660-191273063:0;chr5:0-150543494:0;chr5:150543495-155946409:-1;chr5:155946410-180857866:0;chr6:0-170899992:0;chr7:0-158821424:0;chr8:0-146274826:0;chr9:0-21067715:0;chr9:113585700-114548976:0;chr9:114548977-115764223:-1;chr9:115764224-116210061:0;chr9:116210062-116488534:-1;chr9:116488535-118543174:0;chr9:118543175-121780706:-1;chr9:121780707-127831310:0;chr9:127831311-131697340:-1;chr9:131697341-140273252:0;chr9:21067716-21772164:-1;chr9:21772165-25430149:0;chr9:25430150-29024430:-1;chr9:29024431-29066690:0;chr9:29066691-29253492:-1;chr9:29253493-66579043:0;chr9:66579044-77281262:-1;chr9:77281263-77788424:0;chr9:77788425-93549966:-1;chr9:93549967-93557535:0;chr9:93557536-93911541:-1;chr9:93911542-99260626:0;chr9:99260627-113585699:-1;chrX:0-154913754:0;chrY:0-57772954:0			Biostatistics Department, University of Washington, Seattle, WA, USA	Pretherapy patients with chronic lymphocytic leukemia (CLL) from US Intergroup trial E2997 were analyzed with single nucleotide polymorphism microarrays to detect acquired chromosomal anomalies. The four CLL-typical anomalies (11q-, +12, 13q-, and 17p-) were found at expected frequencies. Acquired anomalies in other regions account for 70% of the total detected anomalies, and their number per participant has a significant effect on progression-free survival after adjusting for the effects of 17p- (and other covariates). These results were compared with those from a previous study of more than 50,000 participants from the GENEVA consortium of genome-wide association studies, which analyzed individuals with a variety of medical conditions and healthy controls. The percentage of individuals with acquired anomalies is vastly different between the two studies (GENEVA 0.8%; E2997 80%). The composition of the anomalies also differs, with GENEVA having a higher percentage of acquired uniparental disomies and a lower percentage of deletions. The four common CLL anomalies are among the most frequent in GENEVA participants, some of whom may have CLL-precursor conditions or early stages of CLL. However, the patients from E2997 (and other studies of symptomatic CLL) have recurrent acquired anomalies that were not found in GENEVA participants, thus identifying genomic changes that may be unique to symptomatic stages of CLL. 	NCBI 36/hg18		phs000621		Yes	NA